argenx (NASDAQ:ARGX) Stock Rating Upgraded by William Blair

argenx (NASDAQ:ARGX) was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Friday, Briefing.com reports.

Several other research analysts also recently issued reports on the company. Wedbush upped their price objective on argenx from $519.00 to $560.00 and gave the stock an “outperform” rating in a report on Friday, July 26th. Wells Fargo & Company upped their price target on argenx from $543.00 to $547.00 and gave the company an “overweight” rating in a research note on Friday, July 26th. Raymond James reiterated a “strong-buy” rating and issued a $605.00 price objective on shares of argenx in a research report on Thursday, October 10th. Barclays raised argenx from an “equal weight” rating to an “overweight” rating in a report on Tuesday, August 6th. Finally, Robert W. Baird raised their target price on shares of argenx from $490.00 to $515.00 and gave the company an “outperform” rating in a research note on Monday, July 29th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $564.61.

argenx Trading Up 6.3 %

Shares of NASDAQ ARGX opened at $586.30 on Friday. argenx has a 1-year low of $327.73 and a 1-year high of $589.60. The company has a 50-day moving average of $536.55 and a two-hundred day moving average of $463.44. The company has a market cap of $34.84 billion, a PE ratio of -103.59 and a beta of 0.63.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Profund Advisors LLC raised its holdings in shares of argenx by 3.0% during the second quarter. Profund Advisors LLC now owns 973 shares of the company’s stock worth $418,000 after acquiring an additional 28 shares during the period. Wealth Alliance lifted its holdings in shares of argenx by 4.8% in the second quarter. Wealth Alliance now owns 628 shares of the company’s stock valued at $270,000 after purchasing an additional 29 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of argenx by 51.3% during the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after buying an additional 40 shares during the period. Toronto Dominion Bank grew its holdings in shares of argenx by 16.5% during the first quarter. Toronto Dominion Bank now owns 303 shares of the company’s stock worth $119,000 after buying an additional 43 shares in the last quarter. Finally, Sequoia Financial Advisors LLC raised its position in argenx by 3.1% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,713 shares of the company’s stock valued at $737,000 after buying an additional 52 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.